<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aligos Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/aligos-therapeutics-inc</link>
<description>Latest news and press releases for Aligos Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aligos-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835453478dffbe2df0e2757.webp</url>
<title>Aligos Therapeutics Inc</title>
<link>https://6ix.com/company/aligos-therapeutics-inc</link>
</image>
<item>
<title>Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-enters-into-exclusive-license-deal-with-xiamen-amoytop-biotech-co-ltd-to-develop-and-commercialize-pevifoscorvir-sodium-in-greater-china-for-chronic-hepatitis-b-virus-infection</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-enters-into-exclusive-license-deal-with-xiamen-amoytop-biotech-co-ltd-to-develop-and-commercialize-pevifoscorvir-sodium-in-greater-china-for-chronic-hepatitis-b-virus-infection</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit</description>
</item>
<item>
<title>Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-first-interim-analysis-results-from-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-in-participants-with-chronic-hepatitis-b-virus-infection-and-grant-of-fda-fast-track-designation</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-first-interim-analysis-results-from-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-in-participants-with-chronic-hepatitis-b-virus-infection-and-grant-of-fda-fast-track-designation</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to</description>
</item>
<item>
<title>Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused</description>
</item>
<item>
<title>Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-to-announce-4th-quarter-2025-financial-results-on-march-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-to-announce-4th-quarter-2025-financial-results-on-march-5-2026</guid>
<pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical c</description>
</item>
<item>
<title>Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-presents-positive-data-at-the-conference-on-retroviruses-and-opportunistic-infections-croi</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-presents-positive-data-at-the-conference-on-retroviruses-and-opportunistic-infections-croi</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado. The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy</description>
</item>
<item>
<title>Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-inducement-grants-130000837</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-inducement-grants-130000837</guid>
<pubDate>Fri, 30 Jan 2026 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employ</description>
</item>
<item>
<title>Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-provides-phase-2-130000811</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-provides-phase-2-130000811</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>Interim analyses on track for the first and second half of 2026SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection. “2026 is an important year for Aligos a</description>
</item>
<item>
<title>Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-strengthens-senior-leadership-130000664</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-strengthens-senior-leadership-130000664</guid>
<pubDate>Tue, 13 Jan 2026 13:00:00 GMT</pubDate>
<description>Seasoned leader with global commercialization and marketing expertiseSOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective immediately. Mr. Hassard will lead and build the Compa</description>
</item>
<item>
<title>Aligos Therapeutics Presents Positive Data at HEP-DART 2025</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-presents-positive-data-130000095</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-presents-positive-data-130000095</guid>
<pubDate>Thu, 11 Dec 2025 13:00:00 GMT</pubDate>
<description>Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from four presentations, including two oral presentations, at the HEP-DART 2025 Me</description>
</item>
<item>
<title>Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-presents-positive-data-130000943</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-presents-positive-data-130000943</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodiumSOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations, including one oral presentation, at the American Association for the Study of</description>
</item>
<item>
<title>Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-reports-recent-business-133000927</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-reports-recent-business-133000927</guid>
<pubDate>Thu, 06 Nov 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China</description>
</item>
<item>
<title>Aligos Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-present-upcoming-investor-133000384</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-present-upcoming-investor-133000384</guid>
<pubDate>Tue, 04 Nov 2025 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences. Jefferies London Healthcare Conference Fireside Chat on Monday, November 17, 2025 at 3:00pm GMT Piper Sandler 37th Annual Healthcare Conference Fireside Chat o</description>
</item>
<item>
<title>Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announce-3rd-quarter-123000885</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announce-3rd-quarter-123000885</guid>
<pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical</description>
</item>
<item>
<title>Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-receives-usan-council-123000809</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-receives-usan-council-123000809</guid>
<pubDate>Thu, 16 Oct 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the United States Adopted Names (USAN) Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, under investigation for the treatment of chronic hepatitis B virus (HBV) infection. The USAN, cons</description>
</item>
<item>
<title>Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-present-h-c-123000080</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-present-h-c-123000080</guid>
<pubDate>Tue, 14 Oct 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright Liver Disease Conference being held October 21 - 22, 2025. A webcast of the presentation will be accessible by visiting the Presentation & Events section on the “Investors”</description>
</item>
<item>
<title>Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-eight-abstracts-123000135</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-eight-abstracts-123000135</guid>
<pubDate>Tue, 07 Oct 2025 12:30:00 GMT</pubDate>
<description>Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight presentations, including one oral presentation, at The Liver Meeting® 2025, being held November 7 –</description>
</item>
<item>
<title>Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-six-preclinical-200500584</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-six-preclinical-200500584</guid>
<pubDate>Wed, 03 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany. The company and its collaborators’ commitment to advancing next-generation therapies fo</description>
</item>
<item>
<title>Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-present-h-c-200500424</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-present-h-c-200500424</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. A webcast of the on demand presentation will be accessible by visiting the Presentation & Events se</description>
</item>
<item>
<title>Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-strengthens-senior-leadership-123000840</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-strengthens-senior-leadership-123000840</guid>
<pubDate>Wed, 20 Aug 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. “I am thrilled to welcome Ramón to the leadership team at Aligos,” said Sushmita Chanda, PhD, DABT, Execu</description>
</item>
<item>
<title>Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection</title>
<link>https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-first-subject-123000862</link>
<guid isPermaLink="true">https://6ix.com/company/aligos-therapeutics-inc/news/aligos-therapeutics-announces-first-subject-123000862</guid>
<pubDate>Wed, 13 Aug 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection. “Despite available treatments for chronic HBV infection, bett</description>
</item>
</channel>
</rss>